Shares in Applied Genetic Technologies (Nasdaq: AGTC) plummeted almost 50% on Thursday, after the firm revealed biotech major Biogen (Nasdaq: BIIB) was tearing up a 2015 deal that could have been worth a billion dollars.
AGTC said top-line interim six-month data from its Phase I/II trial of rAAV2tYF-CB-hRS1, an investigational AAV-based gene therapy showed “no signs of clinical activity.”
Disappointed with the outcome, Biogen has now handed back rights to the XLRS and X-linked retinitis pigmentosa (XLRP) programs as well as three other partnered discovery programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze